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Caspase-1–deficient mice are protected against cisplatin-
induced apoptosis and acute tubular necrosis.
Background. Cisplatin is a commonly used chemotherapeu-
tic agent which causes apoptosis or necrosis of renal tubular ep-
ithelial cells in vitro. Caspases are a family of cysteine proteases
that mediate apoptosis (caspase-3) and inflammation (caspase-
1). Although well studied in vitro, caspases have not been pre-
viously studied in cisplatin-induced acute renal failure (ARF)
in vivo.
Methods. Cisplatin (30 mg/kg) was injected intraperitoneally
into wild-type and caspase-1–deficient (−/−) C57BL/6 mice.
Serum creatinine and blood urea nitrogen (BUN), and renal
caspase-1, -3, -8 and -9 activity were measured on days 1, 2, and
3 after cisplatin injection. Kidneys were examined for acute
tubular necrosis (ATN), neutrophils, and apoptosis on days 1,
2, and 3.
Results. After cisplatin injection, serum creatinine and BUN
were normal on day 1, began to increase on day 2, and peaked
on day 3. Similarly, ATN scores and neutrophil counts peaked
on day 3. In contrast, renal apoptosis significantly increased
on day 2. Renal dysfunction, apoptosis, ATN scores and neu-
trophil infiltration were all reduced in the caspase-1−/− mice.
In wild-type mice, caspase-1 and -3 activity increased on days
2 and 3. Caspase-3 activity was reduced by approximately 50%
in caspase-1−/− mice; active caspase-3 detected by immunoblot
was also reduced in caspase-1−/− mice. In vitro, addition of re-
combinant caspases to kidney cytosolic extracts determined that
caspase-1 activates caspase-3 in renal tissue.
Conclusion. These results indicate that caspase-1 contributes
to cisplatin-induced ARF and ATN (day 3). Furthermore,
caspase-1 affects caspase-3 activation and apoptosis in cisplatin-
induced ARF (day 2).
Cisplatin and other platinum derivatives are front-line
chemotherapeutic agents used in the treatment of solid
tumors, including ovarian, head and neck, and testicu-
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lar germ cell tumors [1, 2]. One of the mechanisms by
which cisplatin is effective against solid cancers is due to
its proapoptotic effects [3]. An important consequence of
cisplatin administration is acute renal failure (ARF); ap-
proximately one third of patients have evidence of renal
dysfunction following cisplatin treatment [4]. The result-
ing nephrotoxicity is a cumulative, dose-dependent ef-
fect which may necessitate dose reduction or withdrawal
of cisplatin treatment. Despite this toxicity, cisplatin re-
mains one of the most commonly used chemotherapy
drugs [2] due to its therapeutic efficacy. An understand-
ing of the pathogenesis of cisplatin-induced ARF is im-
portant for the development of adjunctive therapies to
prevent this complication.
Caspases are a family of intracellular cysteine pro-
teases essential for the execution of apoptosis primar-
ily through the activation of caspase-3 [5]. Caspase-3,
known as the “executioner” caspase, cleaves a variety
of substrates which cause the breakdown of DNA and
the characteristic features of apoptotic cell death: chro-
matin condensation, DNA fragmentation, and formation
of apoptotic bodies [6]. Caspase-3 is activated by “ini-
tiator” caspases (e.g., caspase-8 and -9) [7]. Caspase-1 is
a proinflammatory caspase which converts the cytokines
interleukin (IL)-1b and IL-18 to their active forms [8, 9].
Caspase-1 may also participate in apoptosis though the
activation of caspase-3 [10].
In vitro, cisplatin causes apoptosis or necrosis of renal
proximal tubular cells, depending on the dose used [11].
In vivo, apoptosis and necrosis as well as inflammation
are seen on histology of renal tissue [12–16]. The presence
of apoptosis and necrosis, and the activation of caspase-
3, -8, and -9 have been examined in proximal tubular
cells exposed to cisplatin in vitro [11, 17–20]; however, the
role of these caspases has not been studied in vivo. The
activation of caspase-1 has not previously been identified
in in vitro models of cisplatin injury. One of the aims of
our study, therefore, was to determine the time course
of caspase activation and morphologic injury in cisplatin-
induced ARF in vivo.
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In previous work, we have demonstrated that caspase-
1 is an important mediator of ischemic ARF in mice [21].
In this regard, numerous factors that have been demon-
strated to be pathogenic in ischemic ARF have also been
shown to mediate cisplatin-induced ARF [12, 14, 22–24].
Therefore, we hypothesized that caspase-1 is also a me-
diator of cisplatin-induced ARF.
METHODS
Animals and drug administration
For all the mouse studies, 8- to 10-week-old C57BL/6
mice (Harlan, Indianapolis, IN and Jackson Labs, Bar
Harbor, ME, USA) weighing 20 to 25 g were used. The
caspase-1–deficient (−/−) mice [25], backcrossed ≥8 gen-
erations on a C57BL/6 background, were kindly provided
by Hiroko Tsutsui of the Department of Immunology &
Medical Zoology at Hyogo College of Medicine, Japan.
Deficiency of caspase-1 was confirmed by immunoblot-
ting kidney and spleen for the pro form of caspase-1. Mice
were maintained on a standard diet and water was freely
available. Mice were housed five per cage under a 12-
hour light and dark schedule for at least 1 week prior
to cisplatin administration. Twelve hours before cisplatin
administration, food and water were withheld. Cisplatin
was administered intraperitoneally at a dose of 30 mg/kg,
after which the mice again had free access to food and wa-
ter. Preliminary studies revealed that inconsistent renal
failure occurred when mice had free access to food and
water prior to cisplatin injection and that lower doses
of cisplatin did not cause renal injury. Under anesthesia
with Avertin (2,2,2-tribromoethanol) (Aldrich, Milwau-
kee, WI, USA), kidneys were removed and blood samples
were collected via cardiac puncture 1, 2, or 3 days after
cisplatin administration.
Preparation of drugs
Cisplatin (Aldrich) was freshly prepared the day of
administration in normal saline at a concentration of
1 mg/mL. Mice were given either 30 mg/kg body weight
of cisplatin or vehicle (saline).
Blood urea nitrogen (BUN) and serum creatinine
measurement
BUN and serum creatinine were measured using a
BUN and a creatinine autoanalyzer (Beckman Instru-
ments, Fullerton, CA, USA).
Histologic examination
Paraformaldehyde (4%)-fixed and paraffin-embedded
kidneys were sectioned at 4 lm and stained with periodic
acid-Schiff (PAS) by standard methods. All histologic ex-
aminations were performed by the renal pathologist in a
blinded fashion. Histologic changes due to acute tubular
necrosis (ATN) score were evaluated in the outer stripe of
the outer medulla on PAS-stained tissue and were quanti-
fied by counting the percent of tubules that displayed cell
necrosis, loss of brush border, cast formation, and tubule
dilatation as follows: 0, none; 1, <10%; 2, 11% to 25%;
3, 26% to 45%; 4, 46% to 75%; and 5, >76%. At least 10
fields (200×) were reviewed for each slide.
Neutrophil infiltration was quantitatively assessed on
PAS-stained tissue by the renal pathologist by counting
the number of neutrophils per high powered field (400×).
At least 10 fields were counted in the outer stripe of the
outer medulla for each slide.
Morphologic criteria were used to count apoptotic cells
on PAS-stained tissue by a pathologist experienced in
the evaluation of renal apoptosis. Morphologic character-
istics included cellular rounding and shrinkage, nuclear
chromatin compaction, and formation of apoptotic bod-
ies [26]. Apoptotic tubular cells were quantitatively as-
sessed per high powered field in the outer stripe of the
outer medulla by the renal pathologist in a blinded fash-
ion. At least 10 fields were counted for each slide.
Myeloperoxidase (MPO) assay
MPO activity (kinetic assay) was measured as previ-
ously described with modifications [27]. Snap-frozen kid-
ney samples were homogenized in 3 mL of 20 mmol/L
potassium phosphate buffer, pH 7.4, and then cen-
trifuged for 20 minutes at 40,000 × g at 4◦C. The pellet
was resuspended in 2.5 mL hexadecyltrimethylammo-
nium bromide (HDTB) buffer (13.7 mmol/L HDTB and
50 mmol/L potassium phosphate, pH 6.0) (Sigma Chem-
ical Co., St. Louis, MO, USA). After three freeze and
thaw cycles with sonication between cycles for 90 sec-
onds (Vibracell, Sonic & Materials Inc., Denbury, CT,
USA), the samples were placed in a water bath at 60◦C
for 2 hours. Finally, the samples were again centrifuged
at 16,400 × g for 10 minutes and supernatant was de-
canted. Protein concentration was quantified using the
Lowry assay. Twenty-five microliters of the supernatant
was added to 725 lL of reaction buffer (0.68 mmol/L o-
dianisidine, 50 mmol/L potassium phosphate buffer, pH
6.0, and 29 mmol/L H2O2). The change in absorbance
was measured at 460 nm using a spectrophotometer
(Beckman DU640; Beckman Instruments). MPO activity
was expressed as optical density per minute per milligram
of protein.
In situ detection of DNA fragmentation
The terminal deoxynucleotidyl transferase (TdT)-
mediated nick end labeling (TUNEL) method was used
to detect in situ DNA strand breaks. TACS 2 TdT-blue
label in situ apoptosis detection kit (Trevigen, Gaithers-
burg, MD, USA) was used. Paraffin blocks were sectioned
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at 4 lm thickness on slides. Paraffin sections were de-
paraffinized in xylene and rehydrated in graded ethanols
and phosphate-buffered saline (PBS). The tissue sections
were incubated with proteinase K for 1 hour at 37◦C
for permeabilization. Endogenous peroxidase activity
was quenched by incubating the tissue sections with 3%
H2O2 in methanol for 5 minutes. The sections were then
treated with biotinylated nucleotide, manganese cation
and TdT enzyme for 1 hour at 37◦C. After treating with
streptavidin-horseradish peroxidase (HRP) for 3 minutes
at room temperature, the sections were stained with blue
label for 7 minutes. The tissues were counterstained with
nuclear fast red.
Positive and negative controls for TUNEL stain were
performed. A histologic section of a wild-type C57BL/6
male mouse kidney was treated with TACS-Nuclease
before the TUNEL stain was performed. The vast ma-
jority of the cells exhibited nuclear staining. This TACS-
Nuclease positive control confirmed that the permeabi-
lization and the labeling reaction had worked. In contrast,
a histologic section of kidney stained with the TUNEL
stain in the absence of TdT enzyme demonstrated the
absence of nuclear staining and the presence of the coun-
terstain in all the cells.
TUNEL-positive cells were counted in 10 random ar-
eas in the cortex and outer stripe of outer medulla. All
cells with apoptotic morphology (cellular rounding and
shrinkage, pyknotic nuclei, and formation of apoptotic
bodies) that stained positive with the TUNEL assay were
counted.
Electrochemilumenescence (ECL) assay for IL-1b
The ECL assay for IL-1b in whole kidney homogenates
was performed as previously described in detail [28]. The
ECL assay detects both pro form and mature forms of
IL-1b .
Caspase assays
The activity of caspases was determined by the use
of flourescent substrates as previously described [29]
with modifications [30]. Renal cortex was mixed with a
lysis buffer containing 25 mmol/L Na+ Hepes, 2 mmol/L
dithiothreitol (DTT), 1 mmol/L ethylenediaminete-
traacetic acid (EDTA), 0.1% 3-[(3-cholamidopropyl)
dimethylammonio]-1-pro-panesulfonate (CHAPS),
10% sucrose, 1 mmol/L phenylmethylsulfonyl fluoride
(PMSF), and 1 lmol/L pepstatin A, pH 7.2, and homog-
enized with 10 strokes in a glass-Teflon homogenizer.
The lysate was then centrifuged at 4lC at 100,000g in
a Beckman Ti70 rotor for 1 hour. The resultant super-
natants (cytosolic extracts) were immediately frozen in
liquid nitrogen and stored at –80◦C until use. Lysate
protein was measured by the Bio-Rad DC protein assay
kit (Bio-Rad, Hercules, CA, USA) with bovine serum
albumin (BSA) as standards.
The caspase assay was performed on this super-
natant as follows: 200 lg of protein (20 to 50 lL)
was added to 10 lL of the substrate (final concentra-
tion, 25 lmol/L). The assay volume was made up to
200 lL with caspase assay buffer. The assay buffer for
caspase-3 contained 250 mmol/L potassium + Hepes,
50 mmol/L KCl, 1 mmol/L DTT, 1 mmol/L EDTA, and
0.1% CHAPS, pH 7.4. Ac-Asp-Glu-Val-Asp-7-amido-4-
methyl coumarin (Ac-DEVD-AMC) in 100% dimethyl
sulfoxide (DMSO) was used as a susceptible substrate
for caspase-3 [31]. The assay buffer for caspase-8 and
-9 contained 75 mmol/L Na+ MOPS, 10% glycerol,
1 mmol/L DTT, and 1 mM EDTA, pH 7.4. Ac-Ile-Glu-
Pro-Asp-7-Amino-4-methylcoumarin (IEPD-AMC) in
100% DMSO was used as a susceptible substrate for
caspases-8 and -9 [31]. The assay buffer for caspase-1 con-
tained 100 mmol/L Hepes, 10% sucrose, 10 mmol/L DTT,
0.1 mmol/L EDTA, and 0.1% CHAPS, pH 7.5. Ac-Typ-
Glu-His-Asp-AMC (Ac-WEHD-AMC) in 100% DMSO
was used as a susceptible substrate for caspase-1. The
solution was preincubated for 10 minutes at 30◦C be-
fore substrate was added. The reaction was then initiated
by addition of substrate. Peptide cleavage was measured
over 1 hour at 30◦C using a Cytofluor 4000 series fluores-
cent plate reader (Perseptive Biosystems, Framingham,
MA, USA) at an excitation wavelength of 380 nm and
an emission wavelength of 460 nm. An AMC standard
curve was determined for each experiment. Caspase ac-
tivity was expressed in nmol AMC released per minute
of incubation time per milligram of lysate protein.
The sensitivity of the substrate Ac-WHED-AMC for
caspase-1 was tested using 3 lg of either recombinant
caspase-1 or caspase-11; caspase-1 activity was 165 fluo-
rescent U/min and the caspase-11 activity was 10. Using
0.3 lg of caspase-1 and caspase-11, the caspase-1 activ-
ity was 2.5 fluorescent U/min and the caspase-11 activity
was 0. Thus, the substrate Ac-WEHD-AMC demon-
strates minimal cross-reactivity for caspase-11.
Immunoblotting
Cytosolic extracts of whole kidney were prepared as
described for the caspase assay. The extracts were mixed
with sample buffer containing 50 mmol/L Tris-base (pH
6.8), 0.5% glycerol, 0.01% bromphenol blue, and 0.75%
sodium dodecyl sulfate (SDS) and heated at 95◦C for
5 minutes. Equal amounts of protein (100 lg/lane) were
fractionated by Tris-glycine-SDS-12.5% polyacrylamide
gel electrophoresis (PAGE). The electrophoretically sep-
arated proteins were then transferred to a nitrocellulose
membrane (Millipore, Bedford, MA, USA) by wet elec-
troblotting for 55 minutes. The membranes were blocked
with 5% nonfat dry milk in TBST [50 mmol/L Tris (pH
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Spleen Kidney
Fig. 1. Immunoblot for the pro form of caspase-1 in the spleen and kidney of wild-type and caspase-1−/− mice. Cytosolic extracts of spleen and
kidney were prepared for immunoblotting as described in the Methods section for wild type (+/+) and caspase-1−/− (−/−) mice. The pro form of
caspase-1 is absent in the −/− mice. The immunoblots are representative of three separate experiments.
7.5), 150 mmol/L NaCl, and 0.1% Tween 20] buffer at
pH 7.5 overnight at 4◦C. Immunoblot analyses was per-
formed with a rabbit polyclonal antibody raised against a
recombinant protein corresponding to amino acids 1-277
representing the full-length precursor form of caspase-
3 of human origin (1:1000) (catalogue number sc-7148)
(Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA).
The antibody has species reactivity to human, mouse and
rat. The antibody reacts with the precursor of caspase-3
(also designated as CPP 32) (32 kD) as well as the pro
forms (11 kD and 20 kD). Purified recombinant caspase-
3 (Upstate Group Inc, Lake Placid, NY, USA) contain-
ing the pro form and active form of caspase-3 was used
as a positive control. Primary antibody for caspase-1 was
also used (1:1000) (catalogue number sc-514) (Santa Cruz
Biotechnology, Inc); this antibody detects the precursor
(pro) form of caspase-1. The membranes were incubated
with primary antibodies for 1 hour at room tempera-
ture, washed in TBST buffer, and further incubated with
donkey antirabbit IgG coupled to HRP (Amersham, Pis-
cataway, NJ, USA) (for caspase-3 immunoblot) or don-
key antigoat IgG coupled to HRP (catalogue number sc-
2020) (Santa Cruz Biotechnology, Inc) (for the caspase-
1 immunoblot) at 1:1000 dilution in TBST buffer for 1
hour at room temperature. Subsequent detection was car-
ried out by enhanced chemiluminescence (Amersham),
according to the manufacturer’s instructions. Prestained
protein markers (Bio-Rad) were used for molecular mass
determination.
Statistical analysis
All values are expressed as mean ± standard error
(SE). For single comparisons, normally distributed data
was evaluated using unpaired, two-tailed Student t tests
and nonnormally distributed data were analyzed by the
nonparametric unpaired Mann-Whitney test. Multiple
group comparisons were performed using analysis of vari-
ance (ANOVA) with post test according to Newman-
Keuls. A P value of < 0.05 was considered statistically
significant.
RESULTS
Confirmation of genetic deficiency of caspase-1
To confirm that the caspase-1−/− mice lacked the
caspase-1 protein, immunoblotting for the pro form of
caspase-1 in the kidney and spleen of wild-type and
caspase-1−/− mice was done. As shown in Figure 1, the
pro form of caspase-1 is absent in caspase-1−/− mice.
Renal function in wild-type and caspase-1−/− mice after
cisplatin injection
After injection with cisplatin, serum creatinine and
BUN were unchanged compared to vehicle-treated mice
on day 1, and increased slightly on day 2. Renal dysfunc-
tion was most severe on day 3. Caspase-1−/− mice were
significantly protected against ARF on both days 2 and 3
after cisplatin injection (Fig. 2).
On day 2, serum creatinine (mg/dL) was 0.2 ± 0.1
in vehicle-treated wild-type, 0.1 ± 0.1 in vehicle-treated
caspase-1−/−, 0.3 ± 0.1 in cisplatin-treated wild-type (P <
0.05 vs. vehicle-treated wild-type and vehicle-treated
caspase-1−/−) and 0.1 ± 0.1 in cisplatin-treated caspase-
1−/− (P < 0.05 vs. cisplatin-treated wild-type) (N = 4
to 9) (Fig. 2A). On day 3, serum creatinine was 0.2 in
vehicle-treated wild-type, 0.1 in vehicle-treated caspase-
1−/−, 1.6 ± 2 in cisplatin-treated wild-type (P < 0.001
vs. vehicle-treated wild-type and vehicle-treated caspase-
1−/−), and 0.6 ± 0.1 in cisplatin-treated caspase-1−/−
(P < 0.001 vs. cisplatin-treated wild-type) (N = 6 to 15)
(Fig. 2A).
On day 2, BUN (mg/dL) was 19 ± 1 in vehicle-treated
wild-type, 19 ± 1 in vehicle-treated caspase-1−/−, 43 ± 8
in cisplatin-treated wild-type (P < 0.05 vs. vehicle-treated
wild-type and vehicle-treated caspase-1−/−), and 23 ± 2
in cisplatin-treated caspase-1−/− (P < 0.01 vs. cisplatin-
treated wild-type) (N = 4 to 9) (Fig. 1B). On day 3, BUN
was 14 ± 1 in vehicle-treated wild-type, 16 ± 1 in vehicle-
treated caspase-1−/−, 162 ± 19 in cisplatin-treated
wild-type (P < 0.01 vs. vehicle-treated wild-type and
vehicle-treated caspase-1−/−) and 105 ± 11 in cisplatin-
treated caspase-1−/− (P < 0.001 vs. cisplatin-treated wild-
type) (N = 6 to 15) (Fig. 2B).
Our model of cisplatin-induced ARF is a severe and
irreversible model of cisplatin toxicity. On day 4 after cis-
platin injection, the mice become severely systemically ill,
do not eat or drink, and require sacrifice. Creatinine and
BUN at this time point are not different between caspase-
1−/− mice and wild-type. On day 4, serum creatinine
was 3.3 ± 0.3 in wild-type and 4.3 ± 0.7 in caspase-1−/−
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Fig. 2. Time course of acute renal failure (ARF) after cisplatin injec-
tion in wild-type and caspase-1−/− mice. C57BL/6 wild-type (+/+) and
caspase-1−/− (−/−) mice were injected with 30 mg/kg cisplatin (Cis) or
vehicle (Veh). Animals were sacrificed and blood collected 1, 2 and
3 days after injection. Serum creatinine (A) and blood urea nitrogen
(BUN) (B) remained within normal limits in all groups on day 1. #P
= NS vs. +/+ Veh, −/− Veh, +/+ Cis (N = 5). Renal dysfunction was
most severe on day 3. ∗P < 0.001 vs. ++ Cis days 1 and 2 (N = 5 to
15). Caspase-1−/− mice were functionally protected against cisplatin-
induced ARF compared to wild-type as judged by both serum creatinine
and BUN on day 2 (∗∗P < 0.05 vs. +/+ Cis) (N = 4 to 9) and 3 (∗∗∗P <
0.001 vs. +/+ Cis) (N = 6 to 15).
(P = NS) (N = 4 to 9); BUN was 239 ± 15 in wild-type
and 192 ± 25 in caspase-1−/− mice (P = NS) (N = 4 to 9).
Necrosis, apoptosis, and neutrophil infiltration in
wild-type and caspase-1−/− mice after cisplatin injection
To explore a potential mechanism of protection in
the caspase-1−/− mice, histologic scoring of ATN, neu-
trophils, and apoptosis was performed on days 1, 2, and 3
after injection with cisplatin in wild-type and caspase-
1−/− mice. On days 1 and 2, the ATN score in wild-
type and caspase-1−/− mice was not significantly different
compared to vehicle-treated controls (Fig. 3). On day 3,
the ATN score was 3.7 ± 0.3 in cisplatin-treated wild-type
(P < 0.001 vs. vehicle-treated) and 2.0 ± 0.5 in cisplatin-
treated caspase-1−/− (P < 0.05 vs. cisplatin-treated wild-
type) (N = 9 to 11) (Fig. 3).
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Fig. 3. Acute tubular necrosis (ATN) score in wild-type and caspase-
1−/− mice with cisplatin-induced acute renal failure (ARF). In wild-
type (+/+) mice, ATN scores were not significantly increased until day
3 after cisplatin (Cis) injection. ∗P < 0.001 vs. +/+ Cis days 1 and 2.
On day 3 after cisplatin injection, caspase-1−/− mice (−/−) developed
less severe tubular injury compared to wild-type. ∗∗P < 0.05 vs. +/+ Cis
(N = 9 to 11).
On days 1 and 2, the number of neutrophils in wild-
type and caspase-1−/− was not significantly different com-
pared to vehicle-treated controls (Fig. 4A). On day 3, the
number of neutrophils per high powered field was 11.9 ±
4.3 (N = 11) in cisplatin-treated wild-type (P < 0.001
vs. vehicle-treated) and 1.4 ± 0.9 (N = 9) in cisplatin-
treated caspase-1−/− (P < 0.05 vs. cisplatin-treated wild-
type) (Fig. 4A).
To confirm the histologic findings regarding neutrophil
infiltration, renal MPO activity was determined on days 1,
2, and 3 after cisplatin injection in wild-type and caspase-
1−/− mice. MPO activity is a biochemical assay which
detects both neutrophils and macrophages. MPO activity
followed the same pattern as neutrophil infiltration and
was not significantly increased in wild-type mice until day
3 after cisplatin injection. On day 3, MPO activity was
significantly reduced in the caspase-1−/− mice (Fig. 4B).
Apoptosis did not increase until day 2 after cisplatin
injection. On day 2, the number of apoptotic cells per
high powered field was 4.2 ± 0.4 in cisplatin-treated wild-
type and 2.0 ± 0.1 in cisplatin-treated caspase-1−/− (P <
0.01 vs. cisplatin-treated wild-type) (N = 5). On day 3,
the number of apoptotic cells per high powered field
was 0.8 ± 0.1 in cisplatin-treated wild-type and 1.0 ±
0.1 cisplatin-treated caspase-1−/− (P = NS vs. cisplatin-
treated wild-type) (N = 7 to 9) (Fig. 5A).
To confirm the histologic findings regarding apoptosis,
TUNEL staining was performed on day 1, 2, and 3 af-
ter cisplatin injection in wild-type and caspase-1−/− mice.
TUNEL staining detects DNA strand breaks which occur
during apoptosis. As shown in Figure 5B, TUNEL posi-
tivity mirrored the apoptosis scores and increased signif-
icantly in the wild-type mice on day 2. TUNEL positivity
was significantly reduced in the caspase-1−/− mice on day
2 compared to wild-type.
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Fig. 4. Renal neutrophil count and myeloperoxidase (MPO) activity
in wild-type and caspase-1−/− mice with cisplatin-induced acute renal
failure (ARF). In wild-type (+/+) mice, neutrophil counts (A) and MPO
activity (B) were not significantly increased until day 3 after cisplatin
(Cis) injection. ∗P < 0.001 vs. +/+ Cis days 1 and 2. On day 3, fewer
renal neutrophils were present in caspase-1−/− mice (−/−) compared
to +/+ (∗∗P < 0.05 vs. +/+ Cis) (N = 9 to 11) and MPO activity was
lower in −/− compared to +/+ (∗∗P < 0.01 vs. +/+ Cis) (N = 5 to 7).
The two methods of identifying apoptosis, morpho-
logic criteria on PAS-stained tissue and TUNEL positiv-
ity, were compared by linear regression. The correlation
coefficient (R = 0.89) suggests that the results of these
methods are comparable.
Representative histopathology of ATN, neutrophils,
apoptosis, and TUNEL staining is shown in Figure 6.
Proinflammatory effects of cisplatin-induced ARF
Given the increase neutrophil infiltration and MPO ac-
tivity which coincided with severe renal dysfunction, the
proinflammatory cytokine IL-1b was evaluated on day
3. IL-1b was significantly increased in cisplatin-treated
wild-type compared to vehicle-treated mice. In addition,
IL-1b was significantly lower in the caspase-1−/− mice
(Fig. 7).
Caspase activity in wild-type mice after cisplatin injection
Renal caspase-1, -3, -8, and -9 activity was determined
1, 2, and 3 days after injection of vehicle or cisplatin in
wild-type C56BL/6 mice.
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Fig. 5. Apoptotic tubular cells in wild-type and caspase-1−/− mice
with cisplatin-induced acute renal failure (ARF). The number of apop-
totic cells was significantly increased in wild-type (+/+) cisplatin-
treated (Cis) mice on day 2 compared to days 1 and 3 as assessed by
morphology on periodic acid-Schiff (PAS)-stained tissue (A) and ter-
minal deoxynucleotidyl transferase (TdT)-mediated nick end labeling
(TUNEL) positivity (B). ∗P < 0.01 vs. +/+ Cis days 1 and 3 (N = 5 to
9). Apoptosis on day 2 was significantly reduced in the caspase-1−/−
(−/−) mice as assessed by morphology on PAS and TUNEL positivity.
∗∗P < 0.01 vs. +/+ (N = 5). On day 3, the number of apoptotic cells was
similar between +/+ and −/− (P = NS −/− Cis vs. +/+ Cis) (N = 7
to 9).
No increase in renal caspase activity was noted for any
of the caspases on day 1 after injection. Renal caspase-
1 and -3 activity increased significantly on days 2 and 3
after cisplatin injection compared to vehicle (Figs. 8 and
9). On day 2, renal caspase-1 activity (nmol/min/mg) was
5 ± 1 in vehicle-treated and 15 ± 1 in cisplatin-treated
(P < 0.001 vs. vehicle-treated) (N = 3). On day 3, renal
caspase-1 activity was 13 ± 1 in vehicle-treated and 32 ±
2 in cisplatin-treated (P < 0.001 vs. vehicle-treated) (N =
5 to 7) (Fig. 8). Renal caspase-3 activity (nmol/min/mg)
was 4 ± 1 in vehicle-treated wild type, 91 ± 2 in cisplatin-
treated wild type on day 2 (P < 0.001 vs. vehicle-treated)
(N = 3) and 83.1 ± 14.6 in cisplatin-treated wild type on
day 3 (P < 0.001 vs. vehicle-treated) (N = 5 to 7) (Fig. 9).
Caspase-8 activity did not increase on any of the days
after cisplatin injection (Fig. 10). Caspase-9 activity sig-
nificantly increased only on day 3 (Fig. 10).
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Caspase activity in caspase-1–deficient mice
To further explore the mechanism of protection against
ARF in caspase-1−/− mice, caspase-3, -8, and -9 activ-
ity were determined. Remarkably, the caspase-1−/− mice
had an approximately 50% reduction in caspase-3 activ-
ity compared to wild-type on day 2 (the peak of renal
apoptosis) and day 3 after cisplatin injection (Fig. 9).
On day 3 (the day of peak renal dysfunction), renal
caspase-8 and -9 activity was not significantly different in
the cisplatin-treated wild type compared to the cisplatin-
treated caspase-1−/− mice (data not shown).
Immunoblotting of caspase-3 in caspase-1−/− mice
Caspases exist in the cell cytosol as inactive pro form
and require cleavage to become active. Immunoblots of
cytosolic extracts (from day 3) were performed to detect
the pro (active) form of caspase-3 (Fig. 11). The active
form of caspase-3 (approximately 11 kD) was markedly
increased in cisplatin-treated wild-type mice compared to
vehicle-treated wild-type. Cisplatin-treated caspase-1−/−
mice had a decrease in caspase-3. The intensity of the
band for the pro form of caspase-3 (not shown) was sim-
ilar in all groups.
Effect of caspase-1 on caspase-3 in renal cytosolic extracts
To demonstrate that caspase-1 activates caspase-3 in
the mouse kidney, cytosolic extracts were prepared from
normal wild-type kidney (as described in the Methods
section for the caspase assay). The cytosolic extracts
were incubated with either purified recombinant caspase-
1 or caspase-11 (Fig. 12). Caspase-11, another proinflam-
matory caspase, was also tested. The cytosolic extracts
demonstrated significantly increased caspase-3 activity
when incubated with caspase-1, but not with caspase-11.
Purified caspase-1 and caspase-11 alone did not have sig-
nificant caspase-3 activity confirming that the caspase-
3 substrate Ac-DEVD-AMC (see the Methods section)
does not detect caspase-1 and caspase-11.
DISCUSSION
Cisplatin is a potent chemotherapeutic drug that pro-
motes tumor cell death, in part, by stimulating apoptosis
[3]. ARF is a common complication of cisplatin treat-
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 6. Renal histopathology of wild-type and caspase-1−/− mice with cisplatin-induced acute renal failure (ARF). Periodic acid-Schiff (PAS)-
stained or terminal deoxynucleotidyl transferase (TdT)-mediated nick end labeling (TUNEL) stained kidney tissue, comparable sections and
representative pictures of at least 4 experiments are shown. (A) Vehicle-treated wild-type normal renal proximal tubules (PAS 200×). (B) Cisplatin-
treated wild-type, day 3, severe tubular injury is present in proximal tubules of the outer stripe of the outer medulla with necrotic epithelial cells and
loss of brush border (arrows) (PAS 200×). (C) Cisplatin-treated caspase-1−/−, day 3, necrosis is demonstrated in some tubules (arrows), the normal
tubular structure is preserved in many tubules (PAS 200×). (D) Cisplatin-treated wild-type, day 2, four apoptotic cells are depicted (arrows) (PAS
400×); apoptotic body is present (arrowhead). (E) Cisplatin-treated caspase-1−/−, day 3, the number of apoptotic cells is reduced (arrows) (PAS
400×). (F) Cisplatin-treated wild-type, day 3, TUNEL-positive cells with apoptotic morphology (arrows) (400×) and an apoptotic body (arrow in
insert, 1000×). (G) Cisplatin-treated wild-type, day 3, neutrophils are notably present (circle) (PAS 400×).
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Fig. 7. Renal interleukin (IL)-1b in cisplatin-induced acute renal fail-
ure (ARF) on day 3 in wild-type (+/+) and caspase-1−/− (−/−) mice.
The proinflammatory cytokine IL-1b significantly increased in cisplatin-
treated (Cis) +/+ compared to vehicle-treated (Veh) +/+. ∗∗P < 0.001
vs. +/+ Veh (N = 4 to 5). Renal IL-1b was significantly decreased in
the −/− Veh and −/− Cis compared to +/+ Cis. ∗P < 0.001.
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Fig. 8. Renal caspase-1 activity in cisplatin-induced acute renal fail-
ure (ARF). In wild-type mice (+/+), renal caspase-1 activity did not
increase on day 1 after cisplatin (Cis) injection, but significantly in-
creased on days 2 and 3 compared to vehicle-treated (Veh) mice. #P =
NS vs. Veh (N = 3); ∗P < 0.001 vs. Veh (N = 3); ∗∗P < 0.001 vs. Veh
(N = 5 to 7).
ment, which limits its use [4]. In vitro, cisplatin kills renal
proximal tubule cells by apoptosis or necrosis, depending
on the dose used [11]. In vivo, however, cisplatin-induced
ARF is characterized by apoptosis, necrosis as well as
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Fig. 9. Renal caspase-3 activity in cisplatin-induced acute renal fail-
ure (ARF). In wild-type mice (+/+), renal caspase-3 activity did not
increase on day 1 after cisplatin (Cis) injection, but significantly in-
creased on days 2 and 3 compared to vehicle-treated (Veh) mice. #P =
NS vs. +/+ Veh (N = 3); ∗P < 0.001 vs. +/+ Veh (N = 3 to 7). Caspase-3
activity is lower in caspase-1−/− mice compared to wild-type mice in-
jected with cisplatin on both days 2 and 3, ∗∗P < 0.05 vs. +/+ Cis (N =
3 to 7); ∗∗∗P < 0.001 vs. +/+ Cis (N = 7).
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Fig. 10. Renal caspase-8 and -9 activity in cisplatin-induced acute re-
nal failure (ARF). In wild-type mice (+/+), renal caspase-8 activity
did not increase on day 1, 2 or 3 after cisplatin (Cis) injection com-
pared to vehicle-treated (Veh) mice (day 3 shown). In wild-type mice
treated with cisplatin, renal caspase-9 activity did not increase on day
1 or day 2 compared to wild-type cisplatin-treated; renal caspase-9 ac-
tivity significantly increased on day 3 after cisplatin injection compared
to vehicle-treated mice (day 3 shown). #P = NS vs. Veh (N = 3); ∗P <
0.01 vs. Veh (N = 3).
inflammation on renal histology. To date, a systematic
examination of morphologic injury following cisplatin in-
jection has not been performed. Therefore, we examined
the time course of histologic renal injury regarding apop-
tosis, necrosis, and inflammation.
We determined renal function and morphology on
days 1, 2, and 3 after cisplatin injection in wild-type and
caspase-1−/− mice. Renal dysfunction was most severe
on day 3 after cisplatin injection coinciding histologically
with necrosis and an inflammatory infiltrate. On day 2,
renal dysfunction was minimal; however, renal histology
was characterized by a large increase in apoptosis with
minimal ATN and absent inflammation. Apoptosis on
day 2, necrosis and inflammation on day 3, and renal dys-
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Fig. 11. Western blot of the active form of caspase-3 in cisplatin-
induced acute renal failure (ARF). Cytosolic extracts of kidney tissue
were prepared for immunoblotting as described in the Methods sec-
tion for vehicle-treated wild-type (+/+ Veh), cisplatin-treated wild-type
(+/+ Cis) and cisplatin-treated caspase-1−/− (−/− Cis) mice on day 3
after injection. The active form of caspase-3 (approximately 11 kD)
is consistently increased in the cisplatin-treated wild-type mice com-
pared to the other two groups. The immunoblot is representative of
three separate experiments. Pos is positive control, recombinant active
caspase-3.
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Fig. 12. Effect of caspase-1 on caspase-3 in renal tissue, in vitro. Cy-
tosolic extracts from normal wild-type mice were incubated with re-
combinant purified caspase-1 and -11. Caspase-3 activity was measured
as outlined in the Methods section. In the cytosolic extracts with no
additions (lanes 1 and 6), there was minimal caspase-3 activity. Recom-
binant caspase-1 in the absence of cytosolic extract (57 ng, lane 2; and
5.7 ng, lane 3), did not have caspase-3 activity. Addition of recombinant
caspase-1 (57 ng, lane 4; and 5.7 ng, lane 5) to an aliquot of the same
cytosolic extract (lane 1) resulted in a significant increase of caspase-3
activity. ∗P < 0.001 vs. cytosol alone (lane-1) and caspase-1 alone (lanes
2 and 3); ∗∗P < 0.01 vs. cytosol alone (lane-1) and caspase-1 alone (lanes
2 and 3). Recombinant caspase-11 in the absence of cytosolic extract (57
ng, lane 7; and 5.7 ng, lane 8), did not have caspase-3 activity. Addition
of recombinant caspase-11 (54 ng, lane 9; and 5.4 ng, lane 10) did not
result in caspase-3 activity.
function were reduced in the cisplatin-treated caspase-
1−/− mice compared to wild-type.
The relative contribution of apoptosis, necrosis, and
inflammation to renal dysfunction in cisplatin-induced
ARF is unknown [32]. In other studies where ATN and
apoptosis were examined in cisplatin-induced ARF [13,
14, 33], both forms of cell death were reduced with re-
nal protection; however, these parameters were only ex-
amined at the peak of injury (i.e., day 3 after injection).
We determined that on day 2, apoptosis was most se-
vere while renal dysfunction was minimal, suggesting that
apoptosis may have only a small effect on renal dysfunc-
tion directly. Alternatively, serum creatinine and BUN
may be insensitive markers to detect early changes in
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glomerular filtration rate. It is interesting to note that the
reduction in apoptosis on day 2 in the caspase-1−/− mice
preceded the reduction in necrosis and renal dysfunction
on day 3. This time course of events suggests that apop-
tosis may be the inciting form of cell death that leads to
necrosis and renal dysfunction on day 3. Consistent with
our data is the possibility that the apoptosis seen on day 2
undergoes the phenomenon of secondary necrosis, which
has been noted to occur in cisplatin-induced renal tubular
injury in vitro [11]. In addition, it has been hypothesized
that apoptotic and necrotic cell death likely represent
two ends of a continuum of response to an injury [34–
37]. For example, it has been shown in vitro that shifts
between the two forms of cells death may occur depend-
ing on numerous conditions such as growth factors [38],
oxygen/nutrient availability [39, 40], adenosine triphos-
phate (ATP) concentration [41, 42], and nitric oxide [43].
In cisplatin-induced ARF, many factors (e.g., ATP reduc-
tion [44]) are present which might promote the shift from
apoptotic to necrotic cell death.
Renal neutrophil counts were significantly lower in the
caspase-1−/− mice compared to wild-type mice treated
with cisplatin. This finding was confirmed with MPO ac-
tivity, a biochemical assay which identifies neutrophils
as well as macrophages [45]. This is consistent with
other studies of proinflammatory mediators in cisplatin-
induced ARF which have also noted a reduction in renal
neutrophils associated with renal protection [12–14, 22].
The proinflammatory effect of caspase-1 is due to the
conversion of IL-1b and IL-18 to their active forms. In
response to lipopolysaccharide, caspase-1−/− mice have
a defect in the production of proinflammatory cytokines
(e.g., IL-6 and TNF-a [25, 46]) which is thought to be
a secondary effect from the lack of mature IL-1b and
IL-18 [47]. Similarly, caspase-1−/− mice may have a re-
duction in these proinflammatory mediators in response
to cisplatin. In this regard, an increase in IL-1b mRNA
and the pathogenic role of TNF-a in cisplatin-induced
ARF has recently been reported [12]. To examine the role
of proinflammatory mediators in cisplatin-induced ARF,
IL-1b was studied. IL-1b significantly increased in the
wild-type mice treated with cisplatin and was significantly
reduced in the caspase-1−/− mice. It has been suggested
that inhibition of proinflammatory mediators is protec-
tive in cisplatin-induced ARF due to the reduction in lyso-
somal enzymes and reactive oxygen intermediates from
accumulated leukocytes which can directly damage sur-
rounding tissue [1]. Additionally, activated neutrophils
may up-regulate adhesion molecules and cause adhesion
of leukocytes and subsequent obstruction to blood flow
in the vasculature, further contributing to tubular injury.
We examined the time course of caspase-1, -3, -8, and
-9 activity in cisplatin-induced ARF in wild-type mice. An
increase in renal caspase-1 activity in response to cisplatin
is a novel finding. In vitro, caspase-1 activity does not in-
crease in renal tubular cells after exposure to cisplatin [17,
19, 48]. In vivo, an increase in renal caspase-1 activity or
protein has been demonstrated in numerous forms of re-
nal injury, including ischemia/reperfusion injury [21, 49],
cyclosporine nephrotoxicity [50], and autoimmune lupus
nephritis [51]. The cellular source of caspase-1 activity
in renal injury is unknown. Although neutrophils and
macrophages are known to contain caspase-1, caspase-
1 activity increases prior to the increase in neutrophil
infiltration and MPO activity in cisplatin-induced ARF,
making it unlikely that these cells are a primary source
of caspase-1. Renal tubular proximal tubular cells are a
likely source of caspase-1 as Western blotting of isolated
proximal tubules demonstrates the presence of the pro
form of caspase-1 [52] and caspase-1 activity increases in
freshly isolated rat proximal tubules exposed to hypoxia
[53]. Our results indicate that the activation of caspase-1
in cisplatin-induced ARF requires factors which are ab-
sent in vitro.
The importance of caspase-3 activation leading to cell
death in renal proximal tubular cells is well described in
vitro [17–20]. Specifically, caspase-3 activation precedes
cisplatin-induced cell death and inhibition of caspase-3
is protective [17, 19]. Given the importance of caspase-
3 in mediating proximal tubular cell death in vitro, we
characterized its activation in vivo. Proapoptotic caspases
are either initiators (caspase-8 and -9) or executioners
(caspase-3); activation of initiator caspases causes the
activation of executioner caspases [6]. Caspase-3, the pri-
mary executioner caspase, is activated by one of two path-
ways: (1) death receptor and (2) mitochondrial [7]. The
death receptor pathway is initiated with the engagement
of a cell surface death receptor with its extracellular lig-
and (e.g., FasL, TNF-a) resulting in caspase-8 activation.
The mitochondrial pathway is initiated by cells stressors
(e.g., DNA damage, oxidative stress) resulting in caspase-
9 activation.
In our model of cisplatin-induced ARF, caspase-3 ac-
tivity massively increased on day 2 while caspase-8 ac-
tivity did not increase at any time point. This increase
in caspase-3 coincided with the increase in apoptosis
by histology. These data suggest that the activation of
caspase-3 in cisplatin-induced ARF may not be depen-
dent on caspase-8. Recent work demonstrates the impor-
tance of TNF-a as a mediator of cisplatin-induced ARF
[12, 13]. The mechanism by which TNF-a contributes to
cisplatin-induced ARF remains to be determined; if, how-
ever, TNF-a were contributing to cisplatin-induced ARF
via the death receptor pathway of caspase-3–dependent
apoptosis, an increase in caspase-8 activity would be ex-
pected.
Other factors are known to activate caspase-3, includ-
ing caspase-1 [10], caspase-11, [54] bax and Bcl-2 and re-
active oxygen species [5]. We evaluated the hypothesis
that caspase-1 may activate caspase-3 in cisplatin-induced
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ARF. Caspase-3 activity was approximately 50% reduced
in the cisplatin-treated caspase-1−/− mice compared to
wild-type; additionally, the active form of caspase-3 on
immunoblot was reduced in the caspase-1−/− mice. To
further evaluate this hypothesis, an in vitro experiment
using kidney cytosolic extracts was done. This demon-
strated that caspase-1, but not caspase-11, can activate
caspase-3 in renal tissue. As a whole, our data indi-
cate that caspase-1 is sufficient to activate caspase-3 in
cisplatin-induced ARF, but other factors must also con-
tribute as caspase-3 activation still occurs in the caspase-
1−/− mice.
CONCLUSION
Our data demonstrate that caspase-1 contributes to the
pathogenesis of cisplatin-induced ARF. Caspase-1 activ-
ity increased prior to the development of severe renal
dysfunction and caspase-1−/− mice had less severe ARF
and ATN. Our results suggest two mechanisms whereby
caspase-1−/− mice may be protected against cisplatin-
induced ARF: (1) a reduction in the proinflammatory
cytokine IL-1b and renal neutrophil infiltration and (2)
a reduction in caspase-3 activity associated with a reduc-
tion in apoptosis. Elucidation of the pathways by which
cisplatin mediates cell death in vivo is important for the
development and use of inhibitors which might prevent
cisplatin-induced ARF while not altering the effective-
ness of this chemotherapeutic agent. Studying the role of
caspase-1 is of particular clinical relevance as caspase-1
may be a realistic therapeutic target in the prevention of
cisplatin-induced ARF. Currently, an oral caspase-1 in-
hibitor is available and being used in clinical trials for the
treatment of rheumatoid arthritis [55].
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